Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESK981 in Metastatic Castration-Resistant Prostate Cancer
NCT03456804Phase 2Completed
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- Mar 2018
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CEP-11981 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Barbara Ann Karmanos Cancer Institute. Started Mar 2018; status: completed.
02
Drugs
CEP-11981
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03456804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03456804.